NCT06939816View on ClinicalTrials.gov

Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

November 1, 2026

Conditions
Chronic Kidney Disease Stage 2Chronic Kidney Disease Stage 3Metabolic Dysfunction-Associated Steatohepatitis
Interventions
DRUG

Vonafexor low dose

Oral tablets

DRUG

Vonafexor high dose

Oral tablets

Trial Locations (1)

41460

RECRUITING

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Enyo Pharma
All Listed Sponsors
lead

Enyo Pharma

INDUSTRY

NCT06939816 - Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) | Biotech Hunter | Biotech Hunter